IRVING, Texas, Oct. 10, 2011 /PRNewswire/ -- RBC Life Sciences, Inc. (OTCQB: RBCL) announced today the opening of a new branch office and distribution center in Taiwan, its first office in Asia. The Company opened this office to serve a growing number of independent distributors in Taiwan that were formerly served by its U.S. distribution facility in Irving, Texas. The office will operate under the management of the Company's Asia Regional Director, Mr. Johnny Wang, a 15-year veteran of the direct selling industry in Taiwan.
Clinton Howard, CEO, stated, "The Taiwan office and distribution center will serve as our entry into the large and growing Asian market. We've been working for over a year to establish this office while completing the regulatory requirements and obtaining approval to market a sufficient number of our key products. Our distributors in Taiwan now have local marketing and sales support along with facilities in country where they are able to conduct sales and training meetings, fill product orders and obtain customer service."
About RBC Life Sciences
Through wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's website at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE RBC Life Sciences, Inc.